Author:
Muilwijk D.,de Poel E.,van Mourik P.,Suen S.W.F.,Vonk A.M.,Brunsveld J.E.,Kruisselbrink E.,Oppelaar H.,Hagemeijer M.C.,Berkers G.,de Winter-de Groot K.M.,Heida-Michel S.,Jans S.R.,van Panhuis H.,van der Eerden M.M.,van der Meer R.,Roukema J.,Dompeling E.,Weersink E.J.M.,Koppelman G.H.,Vries R.,Zomer-van Ommen D.D.,Eijkemans M.J.C.,van der Ent C.K.,Beekman J.M.
Abstract
ABSTRACTPatient-derived organoids hold great potential as predictive biomarker for disease expression or therapeutic response. Here, we used intestinal organoids to estimate individual cystic fibrosis transmembrane conductance regulator (CFTR) function of people with cystic fibrosis, a monogenic life-shortening disease associated with more than 2000 CFTR mutations and highly variable disease progression. In vitro CFTR function in CF intestinal organoids of 176 individuals with diverse CFTR mutations was quantified by forskolin induced swelling and was strongly associated with longitudinal changes of lung function and development of pancreatic insufficiency, CF-related liver disease and diabetes. This association was not observed when the commonly used biomarker of CFTR function sweat chloride concentration was used. The data strongly exemplifies the value of an organoid-based biomarker in a clinical disease setting and supports the prognostic value of forskolin induced swelling of intestinal organoids, especially for people with CF who have rare CFTR genotypes with unclear clinical consequences.
Publisher
Cold Spring Harbor Laboratory